利肺健脾汤联合化疗治疗晚期非小细胞肺癌肺脾气虚证的疗效观察  

Clinical efficacy of Lifei Jianpi Decoction combined with chemotherapy for advanced non-small cell lung cancer of lung-spleen qi deficiency syndrome

作　　者：王聪[1] 夏清青[1] 江卫龙[1] 俞新 诸晨静 WANG Cong;XIA Qingqing;JIANG Weilong;YU Xin;ZHU Chenjing(Department of Pulmonology,Jiangyin Hospital of Traditional Chinese Medicine,Jiangyin,Jiangsu 214400)

机构地区：[1]江苏省江阴市中医院肺病科,江苏江阴214400

出　　处：《河北中医》2022年第11期1844-1848,共5页Hebei Journal of Traditional Chinese Medicine

基　　金：无锡市卫生健康委科研项目(编号:Q202055)。

摘　　要：目的观察利肺健脾汤联合化疗治疗晚期非小细胞肺癌肺脾气虚证的临床疗效。方法选择2019年6月至2021年6月江苏省江阴市中医院肺病科晚期非小细胞肺癌肺脾气虚证患者88例,按照随机数字表法分为治疗组与对照组,各44例。对照组采用紫杉醇联合卡铂常规化疗治疗,治疗组在对照组治疗基础上联合利肺健脾汤治疗,2组均治疗2个化疗周期。比较2组治疗前后中医证候评分、血清T淋巴细胞亚群水平及血清糖类抗原125(CA125)、癌胚抗原(CEA)、细胞角蛋白19片段(CYFRA21-1)水平,评价实体瘤治疗效果。结果治疗后2组各项中医证候评分均较本组治疗前降低(P<0.05),且治疗组治疗后显著低于对照组(P<0.05)。治疗后2组CD4^(+)、CD4^(+)/CD8^(+)均较本组治疗前升高(P<0.05),CD8^(+)较本组治疗前降低(P<0.05),且治疗组治疗后CD4^(+)、CD4^(+)/CD8^(+)高于对照组(P<0.05),CD8^(+)低于对照组(P<0.05)。治疗后2组血清CA125、CEA、CYFRA21-1水平均较本组治疗前降低(P<0.05),且治疗组治疗后均低于对照组(P<0.05)。治疗组实体瘤总有效率81.82%(36/44),对照组实体瘤总有效率77.27%(34/44),2组比较差异无统计学意义(P>0.05)。结论利肺健脾汤联合化疗治疗晚期非小细胞肺癌肺脾气虚证能够改善中医证候,提高免疫功能,起到一定的辅助抗癌效果,但对化疗效果尚未形成显著影响。Objective To observe the clinical efficacy of Lifei Jianpi Decoction combined with chemotherapy for advanced non-small cell lung cancer(NSCLC) of lung-spleen qi deficiency syndrome(LSQDS). Methods A total of 88 patients with advanced NSCLC of LSQDS treated in the Department of Pulmonology, Jiangyin Hospital of Traditional Chinese Medicine from June 2019 to June 2021 were randomly assigned into the treatment group(n=44) and the control group(n=44). All patients were managed by routine chemotherapy(paclitaxel plus carboplatin), and those in the treatment group were additionally treated with Lifei Jianpi Decoction. Treated for 2 chemotherapy cycles, the aim was to compare traditional Chinese medicine(TCM) syndrome score, serum T lymphocyte subsets, carbohydrate antigen 125(CA125), carcinoembryonic antigen(CEA), cytokeratin-19 fragment(CYFRA21-1). The treatment effect of solid tumor was assessed.Results After treatment, TCM symptom scores in groups were decreased(P<0.05), which decreased notably in the treatment group compared with the control group(P<0.05). CD4^(+), CD4^(+)/CD8^(+)in groups were increased(P<0.05), while CD8^(+)was decreased(P<0.05). Significantly higher CD4^(+)and CD4^(+)/CD8^(+)levels, and significantly lower CD8^(+)levels were detected in the treatment group as compared to the control group(all P<0.05). CA125, CEA, CYFRA21-1 in groups were decreased(P<0.05), which were more pronounced in the treatment group compared with the control group(P<0.05).The difference was not statistically significant in the overall effective rate of solid tumor treatment between the treatment group and the control group(81.82% [36/44] vs 77.27% [34/44], [P>0.05], respectively).Conclusion For patients with advanced NSCLC of LSQDS, Lifei Jianpi Decoction combined with chemotherapy can improve TCM syndromes and immune function, and with a certain assisted anti-cancer effect. However, no significant effect of chemotherapy has been found.

关 键 词：癌 非小细胞肺 化疗 肺脾气虚证 中西医结合疗法 T淋巴细胞亚群 生物标记 肿瘤 

分 类 号：R734.205.8[医药卫生—肿瘤]